Flare Therapeutics Presents Updated FX-909 Phase 1A Data In Late-Breaking Oral Presentation At 2026 ASCO Genitourinary Cancers Symposium

(MENAFN - GlobeNewsWire - Nasdaq) Data support emergence of differentiating clinical benefit with a favorable safety and tolerability profile for patients with advanced UCCAMBRIDGE, Mass., Feb. 27, ...